FOR IMMEDIATE RELEASE:

Jellyfish Protein Shows Powerful Anti-Aging Potential as a Dietary Supplement

ANAHEIM, California (March 23, 2006)

Quincy Bioscience (Madison, WI) announces that Prevagen™ (www.Prevagen.com), a dietary supplement consisting of the jellyfish protein aequorin, has displayed potent anti-aging activity in their laboratory studies. Quincy Bioscience has been researching the jellyfish protein for the past ten years and will be releasing their first product derived from that technology in the form of an orally acceptable dietary supplement product branded as PrevagenT. Specifically, the anti-aging potential displayed is an ability to keep brain cells alive longer in controlled tests. Laboratory tests show a 28-45% improvement in cellular protection from death in their rodent models studied. Quincy Bioscience is exhibiting their product and sharing this breakthrough for the first time at the 2006 ExpoWest Convention held in Anaheim, California.

Quincy Bioscience sponsors research conducted at the University of Wisconsin at Milwaukee to develop aequorin-based technologies and the first fruit of that relationship is the supplement PrevagenT. PrevagenT is a novel product that in technical terms acts is a calcium-binding protein. Calcium-binding proteins deplete in several areas of the body as part of the aging process. PrevagenT taken as a supplement replaces those proteins lost through aging and provides protection within the cells that it enters.

"We are very excited to be bringing this technology to the market in the form of a dietary supplement," commented Mark Underwood, the inventor of the aequorin technology and a founder and President of Quincy Bioscience. "Many people are searching for a potent anti-aging supplement that has some really strong science supporting that type of claim. There isn't anything on the shelves that matches up with our data."

A certain species of jellyfish contains the protein aequorin which has the unique property of binding calcium ions in their nervous system. Humans also need this type of protein in their nervous system to properly protect their cells too. One of the detriments of the aging process is that humans lose a significant amount of their own cell-protecting proteins. Aequorin is a very similar type of protein and is completely non-toxic, the reason for its successful development into the supplement product.

The response to the technology was very positive from pharmaceutical companies also. Since aequorin is an all natural protein it can be marketed as a dietary supplement and in the future go through clinical trials with the goal of getting FDA approval towards neurodegenerative diseases. Quincy Bioscience will also be speaking at the Biotechnology Industry Organization (BIO) next month in Chicago, Illinois explaining the technology to interested pharmaceutical partner candidates.

"Having strong science is the key to providing a quality product to our consumer base," added Mike Beaman Mr. Underwood's partner in Quincy Bioscience. "It is exciting that we can touch the health of so many others immediately through the supplement product and it is something to see how many people have already asked for the product and are starting to tell their friends and family."

Consumer demand has been growing for the protein as news of aequorin's potential came out of the University laboratory. However, jellyfish protein used to be very difficult to obtain and expensive. Two tons of jellyfish would only yield 125mg of aequorin. Now with safe production techniques the protein is readily available for the market's demand and is made through an all-natural biological process. Quincy Bioscience is increasing capacity to meet international demand with interest expressed in the technology in Europe, Asia and Australia in addition to the North American marketplace.

Quincy Bioscience is a biotechnology company based in Madison, Wisconsin. Quincy Bioscience is focused on the discovery, development and commercialization of novel compounds to fight the disease of aging. The company's therapeutic products focus on restoring calcium balance related to neurodegenerative disorders and the destructive age-related mechanisms triggered by calcium. Quincy Bioscience is set apart by its cutting-edge health applications of the jellyfish protein aequorin. Aequorin has proven neuroprotective activity and is being developed for pharmaceutical product applications.

For more information, contact Mark Underwood, President at munderwood@quincybioscience.com or 414-303-0814.